Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men

Clinical Drug Investigation

Volumn 32, Issue 11, 2012, Pages 761-769

  Tong, Gary ^a   Castaneda, Lorna ^a   Wang, Jun Sheng ^a   Sverdlov, Oleksandr ^a   Huang, Shu Pang ^a   Slemmon, Randy ^a   Gu, Huidong ^a   Wong, Oi ^a   Li, Hewei ^a   Berman, Robert M ^a   Smith, Christina ^a   Albright, Charles ^a   Dockens, Randy C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; CEFAZOLIN; CEFEPIME; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASEPTIC MENINGITIS; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POSTDURAL PUNCTURE HEADACHE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; AREA UNDER CURVE; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; MALE; OXADIAZOLES; PEPTIDE FRAGMENTS; SULFONAMIDES;

EID: 84873442543     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0006-4     Document Type: Article

References (34)

1. Kinkingnehun S, Sarazin M, Lehericy S, et al. VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study. Neurology. 2008;70(23):2201-11.
2. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17(2):101-18.
3. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131(2):215-21.
4. Henley DB, May PC, Dean RA, et al. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2009;10(10):1657-64.
5. Ghosh AK, Brindisi M, Tang J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem. 2012;120(Suppl 1):71-83.
6. Broersen K, Rousseau F, Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Res Ther. 2010;2(4):12.
7. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110(4):1129-34.
8. George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet. 1992;2(4):330-4.
9. Mullan M, Houlden H, Windelspecht M, et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat Genet. 1992;2(4):340-2.
10. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 1992;258(5082):668-71.
11. Van Broeckhoven C, Backhovens H, Cruts M, et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet. 1992;2(4):335-9.
12. Comery TA, Martone RL, Aschmies S, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25(39):8898-902.
13. Martone RL, Zhou H, Atchison K, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009;331(2):598-608.
14. Panza F, Solfrizzi V, Frisardi V, et al. Beyond the neurotransmitter- focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. Aging Clin Exp Res. 2009;21(6):386-406.
15. Neugroschl J, Sano M. An update on treatment and prevention strategies for Alzheimer's disease. Curr Neurol Neurosci Rep. 2009;9(5):368-76.
16. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770-6.
17. Kadesch T. Notch signaling: a dance of proteins changing partners. Exp Cell Res. 2000;260(1):1-8.
18. Gillman KW, Starett JJE, Parker MF. Discovery and evaluation of BMS-708163, a potent, selective, and orally bioavailable gamma secretase inhibitor. ACS Med Chem Lett 2010;1(3):120-124.
19. Meredith J, Albright CF, Dockens R, et al. BMS-708163, a notch-sparing GSI, decreases central Aβ in rats, dogs, and humans with a therapeutic margin relative to notch toxicity. Neurodegenerative Dis 2011;8(S1):1.
20. Tong G, Castaneda L, Wang J-S, et al. A study to evaluate the effects of single oral doses of BMS-708163 in the cerebrospinal fluid of healthy young men. Alzheimer's Dementia. 2010;6(4):S143.
21. Wang J-S, Castaneda L, Sverdlov A, et al. A placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-708163 in healthy young and elderly subjects. Alzheimer's Dementia. 2010;6(4):S540.
22. Dockens R, Karkas J, Zheng M, et al. Effect of concomitant administration of multiple doses of BMS-708163 on safety, tolerability, and the pharmacokinetics of midazolam, warfarin, caffeine, omeprazole, and dextromethorphan in healthy male subjects by administration of a modified Cooperstown cocktail. Alzheimer's Dementia. 2010;6(4):S536.
23. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-93.
24. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66(1):48-54.
25. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28(3):126-32.
26. Siemers ER. How can we recognize "disease modification" effects? J Nutr Health Aging. 2009;13(4):341-3.
27. Gu H, Deng Y, Wang J, et al. Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(25):2319-26.
28. Perrier D, Gibaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci. 1982;71(4):474-5.
29. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980;8(5):509-34.
30. Waring J, Slats D, Gonzalez C, et al. An assessment of variability in CSF biomarkers in clinical experimental models: a meta-analysis. Alzheimer's Dementia. 2012;7(4):S101.
31. Burton CR, Meredith JE, Barten DM, et al. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem. 2008;283(34):22992-3003.
32. Lanz TA, Karmilowicz MJ, Wood KM, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006;319(2):924-33.
33. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol. 2007;30(6):317-25.
34. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65(8):1031-8.